|
gptkbp:instanceOf
|
gptkb:drug
5α-reductase inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
1992
|
|
gptkbp:ATCCode
|
G04CB01
|
|
gptkbp:availableOn
|
generic medication
|
|
gptkbp:bioavailability
|
63%
|
|
gptkbp:brand
|
gptkb:Propecia
gptkb:Proscar
|
|
gptkbp:CASNumber
|
98319-26-7
|
|
gptkbp:chemicalClass
|
steroid-like
|
|
gptkbp:chemicalFormula
|
C23H36N2O2
|
|
gptkbp:contraindication
|
children
pregnancy
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:discoveredBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
4.8-7.1 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
finasteride
|
|
gptkbp:interactsWith
|
gptkb:dihydrotestosterone
gptkb:dutasteride
testosterone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits type II 5α-reductase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:metabolites
|
inactive
|
|
gptkbp:molecularWeight
|
372.549 g/mol
|
|
gptkbp:notRecommendedFor
|
gptkb:women
children
|
|
gptkbp:patentExpired
|
2013
|
|
gptkbp:pregnancyCategory
|
D
X
X (contraindicated)
|
|
gptkbp:pregnancyWarning
|
may cause birth defects in male fetus
|
|
gptkbp:prescribes
|
enlarged prostate
androgenetic alopecia
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:proteinBinding
|
90%
|
|
gptkbp:PubChem_CID
|
gptkb:DB01216
|
|
gptkbp:reduces
|
dihydrotestosterone (DHT) levels
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
decreased libido
gynecomastia
erectile dysfunction
|
|
gptkbp:synonym
|
gptkb:MK-906
gptkb:N-(1,1-dimethylethyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide
|
|
gptkbp:usedFor
|
gptkb:benign_prostatic_hyperplasia
male pattern baldness
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
no
|
|
gptkbp:bfsParent
|
gptkb:Propecia
gptkb:Proscar
|
|
gptkbp:bfsLayer
|
5
|